$MXRX · MED-X, INC.
Med-X, Inc. filed Amendment No. 5 to its S-1 to register resale of up to 16,248,842 post-split common shares by existing stockholders in connection with a direct listing on Nasdaq Global Market under symbol MXRX. The company raised approximately $38,081,204 in net proceeds from inception (Feb 14, 2014) through Oct 14, 2026 at an average post-split price of $2.89 per share. A 1-for-2 reverse stock split was approved June 1, 2026, effective before listing. The company will not receive proceeds from stockholder resales.
- Registers resale of up to 16,248,842 post-split common shares via Nasdaq direct listing.
- No firm-commitment underwriter; Maxim Group LLC engaged as financial advisor.
- Raised ~$38,081,204 net proceeds from inception through Oct 14, 2026 at avg $2.89/share post-split.
- 1-for-2 reverse stock split approved June 1, 2026, effective before listing.
- Chairman/CEO controls ~54.3% of total voting power via Series A super voting preferred stock.
Price data unavailable.
A micro-cap natural-products company is pursuing a Nasdaq direct listing with no underwriter, concentrated insider voting control, and ongoing net losses.
Direct listing without a firm-commitment underwriter is a novel listing method that can produce higher opening volatility than a traditional IPO.
Nasdaq listing approval is not assured and is a condition to the offering; failure means the direct listing is terminated. No public market currently exists and private transaction prices may bear little relation to the opening public price.